Loading company
Sana Biotechnology, Inc.
SANA · Nasdaq · ·
Next earnings: November 5, 2026
$2.92-0.7%Sep 29 close
- 1M
- -23.8%
- 6M
- -4.3%
- 1Y
- -21.1%
- 5Y
- -87.0%
SANA · Nasdaq · ·
Next earnings: November 5, 2026
$2.92-0.7%Sep 29 close
Sana Biotechnology, Inc. is scheduled to report next on November 5, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Profit | -$63.6M | -$93.8M | +32.16% |
| Profit per share | -$0.22 | -$0.39 | +43.59% |
| Free Cash Flow | -$34.4M | -$33M | -4.31% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Sana Biotechnology, Inc. has no earnings call transcript available.
“Our team is executing on our goals of beginning clinical studies soon for both SC451 in type 1 diabetes and SG293 in non-Hodgkin lymphoma,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, WA, Cambridge, MA, and South San Francisco, CA.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Sana Biotechnology, Inc.’s Item 2.02 8-K filed August 10, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.